Recall of Nitroglycerin Injection in 5% Dextrose USP by Advanced Pharma due to sub-potency

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

ISSUE: Advanced Pharma, Inc. d/b/a Avella of Houston (“Advanced Pharma”) is voluntarily recalling all unexpired lots of Nitroglycerin products that were produced at Advanced Pharma’s Houston location between March 3, 2017 and May 31, 2017 to the hospital/user level. The recall is being issued based on laboratory test results indicating a lower than expected potency on certain lots of compounded NitroGlycerin Injection which would lead to a lower dose being administered. While the lower than expected potency results affected only certain lots of Nitroglycerin, Advanced Pharma is recalling all unexpired lots of NitroGlycerin. To date, Advanced Pharma has not received any reports of product complaints and/or adverse events related to the products.

Although nitroglycerin is titrated based on clinical response, an extreme and unexpected reduction in dose than expected could lead to a delay in treatment, disruption of clinical care of the patient, and worsening of patient’s conditions.

The recalled NitroGlycerin products include the 100 mcg per mL and 200 mcg per mL strengths available in 5 mL, 10 mL, and 20 mL sterile single dose syringes and are packaged in various sizes per carton. These products were not distributed directly to patients or consumers, but rather to healthcare facilities (e.g. hospitals) nationwide in the USA between March 9, 2017 to June 1, 2017 and have expiration dates ranging from June 9, 2017 to August 15, 2017. The issue is segregated to the Houston location and no other Avella locations are involved or affected.

BACKGROUND: Nitroglycerin Injection in 5% Dextrose, USP is indicated for treatment of high blood pressure before, during or after surgery; for control of heart failure after a heart attack; for treatment of heart related chest pain in patient...

Recommended for you

  • MedWatch Drug Updates
  • 1 comment

Recall of Riomet (Metformin Hydrochloride Oral Solution) by Sun Pharmaceutical: Presence of microbial contamination

  • MedWatch Drug Updates
  • no comment

Recall of pharmacist choice alcohol prep pads by simple diagnostics due to quality concerns.

  • MedWatch Drug Updates
  • 1 comment

Fading print on label of AlbuRx 25, Albumin (Human) 25% solution

  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Biotin (Vitamin B7) interferes with certain lab tests

  • MedWatch Drug Updates
  • 1 comment

FDA investigated life-threatening adverse events associated with Limbrel Capsules by Primus Pharmaceuticals

  • MedWatch Drug Updates
  • no comment

Recall of Diphenoxylate Hydrochloride and Atropine Sulfate by Greenstone: Sub-potent or super-potent product

  • MedWatch Drug Updates
  • 1 comment

Recall of Nexterone (amiodarone HCl) 150 mg/100 mL premixed injection by Baxter- Presence of particulate matter

  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Increased risk of heart-related death with febuxostat (Uloric)

  • MedWatch Drug Updates
  • 1 comment

FDA update: Type III endoleaks associated with the use of endovascular graft systems

  • MedWatch Drug Updates
  • 1 comment

FDA warns against use of injectable silicone for body contouring and enhancement

  • MedWatch Drug Updates
  • 1 comment

FDA update: High risk of mortality and neurological adverse events when using SynCardia's TAH-t C2 Driver System

  • MedWatch Drug Updates
  • no comment

Class I Recall of Bridge Occlusion Balloon Catheter Model 590-001 by Spectranetics: Blocked guidewire lumen

  • FDA Drug Updates
  • 1 comment

FDA approved Aliqopa (copanlisib) for the treatment of relapsed follicular lymphoma

  • FDA Drug Updates
  • 1 comment

FDA approved Mvasi (bevacizumab-awwb) for the treatment of cancer

  • MedWatch Drug Updates
  • 1 comment

FDA safety alert for compounded glutamine, arginine, and carnitine product for injection by United Pharmacy

  • MedWatch Drug Updates
  • 1 comment

Recall of DBA pain relief naturally products by Ridge Properties: Violation of GMP

  • MedWatch Drug Updates
  • 1 comment

Voluntary field action for Infant/Child Reduced Energy Defibrillation Electrodes by Cardinal Health

  • MedWatch Drug Updates
  • 1 comment

FDA recommends separate dosing for Kayexalate (sodium polystyrene sulfonate) from all other oral drugs

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Intra-Aortic Balloon Pump by Datascope/MAQUET- False blood detection alarm and ingress of fluid into the pump

  • MedWatch Drug Updates
  • 1 comment

Recall of Midazolam injection, USP, 2 mg/2 mL by Fresenius Kabi: contains different drug

  • MedWatch Drug Updates
  • 1 comment

FDA statement on risks of unapproved use of Keytruda (pembrolizumab) for treatment of multiple myeloma

  • MedWatch Drug Updates
  • 1 comment

Recall of Piyanping Anti-Itch Lotion by Lucky Mart Inc.: Contain wrong active pharmaceutical ingredient

  • MedWatch Drug Updates
  • 1 comment

FDA update: Risk of major adverse cardiac events with the use of Absorb GT1 Bioresorbable Vascular Scaffold

  • FDA Drug Updates
  • 1 comment

FDA approves Besponsa (inotuzumab ozogamicin) for acute lymphoblastic leukemia

  • FDA Drug Updates
  • 1 comment

New targeted treatment approved for relapsed or refractory acute myeloid leukemia

  • MedWatch Drug Updates
  • no comment

Voluntary market withdrawal of Octagam 10% immune globulin IV (human) liquid preparation by Octapharma

  • MedWatch Drug Updates
  • 1 comment

Recall of injectable products by SCA Pharmaceuticals: Products may contain microbial contamination

  • MedWatch Drug Updates
  • 1 comment

Class I recall of Penumbra 3D Revascularization device by Penumbra: delivery wire may break or separate during use

  • FDA Drug Updates
  • 1 comment

FDA approved Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for Hepatitis C

  • FDA Drug Updates
  • 1 comment

FDA approved Nerlynx (neratinib) for breast cancer